Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -110.00K | -156.00K | -100.00K | -300.00K | -192.00K | -322.00K |
EBITDA | -109.89M | -108.27M | -91.03M | -46.53M | -35.78M | -33.69M |
Net Income | -116.49M | -109.36M | -76.43M | -46.09M | -41.01M | -47.66M |
Balance Sheet | ||||||
Total Assets | 709.27M | 496.77M | 368.00M | 200.21M | 92.41M | 122.09M |
Cash, Cash Equivalents and Short-Term Investments | 694.66M | 489.88M | 360.38M | 194.61M | 88.04M | 1.21M |
Total Debt | 30.64M | 30.00M | 2.10M | 1.33M | 1.65M | 21.64M |
Total Liabilities | 48.90M | 53.19M | 22.88M | 23.61M | 156.61M | 4.82M |
Stockholders Equity | 660.36M | 443.59M | 345.12M | 176.60M | -64.20M | 117.27M |
Cash Flow | ||||||
Free Cash Flow | -102.99M | -94.43M | -73.55M | -42.40M | -27.60M | -32.73M |
Operating Cash Flow | -101.70M | -93.93M | -73.46M | -42.25M | -27.53M | -32.71M |
Investing Cash Flow | -564.90M | -292.33M | -89.00K | -151.00K | -68.00K | -22.00K |
Financing Cash Flow | 446.67M | 218.31M | 239.38M | 148.98M | 89.93M | 34.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $2.09B | 3.20 | 60.26% | ― | 25.96% | ― | |
58 Neutral | $1.64B | ― | -5.78% | ― | 25.50% | 64.63% | |
52 Neutral | $2.01B | ― | -38.04% | ― | -82.38% | -164.76% | |
50 Neutral | kr5.44B | 12.69 | -80.61% | 5.08% | 37.36% | 27.71% | |
50 Neutral | $1.65B | ― | -70.58% | ― | 100.03% | 64.22% | |
46 Neutral | $1.87B | ― | 18.68% | ― | 41.67% | 75.79% | |
43 Neutral | $1.84B | ― | -23.34% | ― | ― | -14.19% |
On January 21, 2025, Disc Medicine announced positive feedback from the FDA regarding their APOLLO post-marketing confirmatory trial for bitopertin, a treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The meeting resulted in alignment on the trial design, which includes key features such as co-primary endpoints and a double-blind, placebo-controlled study. The company plans to initiate the trial by mid-2025 and anticipates submitting a New Drug Application in the second half of 2025 under the Accelerated Approval Program. This development marks a significant step forward in potentially providing a life-changing therapy for EPP patients, enhancing Disc Medicine’s position in the biopharmaceutical industry.